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Available online 6 October 2016Chronic kidney disease (CKD) is a global health problem, and novel therapies to treat CKD are urgently needed.
Here, we show that inhibition of G0/G1 switch 2 (G0s2) ameliorates renal inﬂammation in amousemodel of CKD.
Renal expression of chemokine (C-C motif) ligand 2 (Ccl2) was increased in response to p65 activation in the
kidneys of wild-type 5/6 nephrectomy (5/6Nx) mice. Moreover, 5/6Nx Clk/Clk mice, which carry homozygous
mutations in the gene encoding circadian locomotor output cycles kaput (CLOCK), did not exhibit aggravation
of apoptosis or induction of F4/80-positive cells. The renal expression of G0s2 in wild-type 5/6Nx mice was
important for the transactivation of Ccl2 by p65. These pathologies were ameliorated by G0s2 knockdown.
Furthermore, a novel small-molecule inhibitor of G0s2 expression was identiﬁed by high-throughput chemical
screening, and the inhibitor suppressed renal inﬂammation in 5/6Nx mice. These ﬁndings indicated that G0s2
inhibitors may have applications in the treatment of CKD.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Chronic renal disease
Circadian clock
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Small compound inhibitor1. Introduction
Chronic kidney disease (CKD) is a global health problem (Barsoum,
2006; Hedayati et al., 2008; Murray, 2008; Enomoto et al., 2008;
Krishnan and Kiernan, 2007). Therapeutic strategies for the treatment
of CKD involve attenuation of progressive renal dysfunction, blood
pressure control, reduction of proteinuria, and exclusion of uremic
toxins (Ruggenenti et al., 1998, 1999; Niwa and Ise, 1994; Ruggenenti
et al., 2012; Codreanu et al., 2005). Although inhibition of the renin-an-
giotensin-aldosterone pathway and elimination of uremic toxins conferaceutics, Division of Clinical
ces, Faculty of Pharmaceutical
Fukuoka 812-8582, Japan.
. This is an open access article underrenal protection, there are no adequate treatments available for allevia-
tion of all the symptoms of CKD.
Most living organisms exhibit behavioral and physiological rhythms
with a periodicity close to 24 h (Vitaterna et al., 1994; Kume et al., 1999;
Jin et al., 1999; Preitner et al., 2002). Mammalian clock genes regulate
biological functions in the central and/or peripheral tissues (Ueda et
al., 2002; Siepka et al., 2007; Isojima et al., 2005). Molecular dissection
of the circadian biological clock has revealed links between genetic
mutations and/or alteration of clock genes and diseases, including
cancer, metabolic syndrome, and diabetes, in humans and animal
models (Filipski et al., 2005; Ohdo et al., 2011). In patients with CKD,
the rhythms of sleep and serum hormone levels are dysregulated
(Niemczyk et al., 2006). Moreover, many mediators of inﬂammation
contribute the pathology of CKD (Yu et al., 2014), and the activities of
these inﬂammatorymediators in various inﬂammatory disorders reveal
the circadian characteristics of the diseased state (Hashiramoto et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protein circadian locomotor output cycles kaput (CLOCK) was shown
to be important for nuclear factor-kappaB (NF-κB)-mediated transcrip-
tion of various pro-inﬂammatory cytokines (Spengler et al., 2012;
Narasimamurthy et al., 2012). Indeed, although it is difﬁcult to discern
causes from effects, these insights have suggested that there may be a
relationship between the molecular clock and CKD pathology. Thus,
elucidation of these relationships may facilitate the development of
new therapies for treating CKD.
The use of high-throughput screening (HTS) techniques has long
been employed by the pharmaceutical industry to increase discovery
rates for new drugs that could be useful for disease treatment (Brey et
al., 2011; Patel et al., 2012). Additionally, chemical screening has
emerged as a powerful tool to investigate biological mechanisms and
other processes (Hirota and Kay, 2009; Hirota et al., 2010; Isojima et
al., 2005). Inﬂammation is a risk factor for various pathological condi-
tions, such as renal disease, hepatitis, diabetes, and cardiovascular
diseases (Meijer et al., 2015). Chronic inﬂammation is affected by acti-
vation of the NF-κB pathway, a prototypical pro-inﬂammatory signaling
pathway; NF-κB induces the expression of various pro-inﬂammatory
genes, including cytokines, chemokines, and adhesion molecules
(Toby, 2009). Because NF-κB has various biological functions, targeting
NF-κB in therapeutic strategies for inﬂammatory diseases is complicat-
ed (Toby, 2009). Therefore, identiﬁcation of novel factors regulating
inﬂammation in disorders such as CKD is urgently needed to facilitate
the discovery of new therapeutic agents.
In this study, we aimed to identify the novel molecular mechanisms
that mediate renal dysfunction in mice with CKD by examining the
relationships between the circadian clock and CKD aggravation. Our
data showed that the expression of the gene encoding G0/G1 switch 2
(G0s2), controlled by the molecular clock pathway (Turek et al.,
2005), increased transcriptional activation of Ccl2 and that G0s2 knock-
down or inhibition by a novel small-molecule inhibitor ameliorated
renal inﬂammation in CKD. Thus, our data suggested that molecular
clock-dependent changes in G0s2 expression aggravated renal inﬂam-
mation in CKD mice.
2. Results
2.1. Renal CLOCK Expression Was Altered in Wild-Type 5/6Nx Mice
First, we sought to elucidate the association between the molecular
clock and CKD pathology. We found that 24-h locomotor activities
were altered in mice that underwent nephrectomy (hereafter referred
to as 5/6Nx mice) at 7–9 weeks after the second operation (Fig. S1A).
To evaluate the renal clock genes involved in various renal functions,
we quantiﬁed the temporal expression proﬁles of renal clock genes in
5/6Nx mice. Renal Clock, Bmal1, Per1, Per2, Cry1, Rev-erbα, Dbp, and
Pparα mRNA expression oscillated in wild-type sham-operated mice
at 8 weeks after operation (Fig. 1A). The expression of clock genes con-
taining cis-element E-boxes increased. Additionally, wild-type 5/6Nx
mice exhibited increased expression of CLOCK protein (Fig. 1B), a
critical regulator of renal function (Zuber et al., 2009; Nikolaeva et al.,
2012). These results suggested that there may be a relationship
between increased CLOCK expression and CKD pathology.
Thus, we further examined the role of CLOCK in 5/6Nx mice using
Clock mutant mice (Clk/Clk), which exhibit more severe behavioral
and molecular phenotypes than Clock-knockout mice (Debruyne et al.,
2006). The Δ19 Clock mouse, which carries a deletion of exon 19 in
the Clk locus, produces a protein that has been characterized as domi-
nant negative by some researchers, but as functionally null by others
(Gekakis et al., 1998). After the second operation at Zeitgeber time
(ZT) 6, serum creatinine and serum urea nitrogen (SUN) levels were in-
creased at 8weeks inwild-type 5/6Nxmice, but decreased at 8weeks in
Clk/Clk 5/6Nx mice (Fig. 2A). The decrease in glomerular ﬁltration rates
(GFRs) in wild-type 5/6Nx mice at 8 weeks was ameliorated in Clk/Clkmutant mice (Fig. S1C). The region of renal ﬁbrosis, indicated by blue
staining of histological sections subjected to Masson's trichrome
staining, decreased markedly in Clk/Clk 5/6Nx mice (Fig. 2B). The area
of terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL)-positive cells, as a marker of apoptosis, and the activity of cas-
pase 3/7were suppressed in Clk/Clk 5/6Nxmice comparedwith those in
wild-type mice (Fig. 2C). Functional microarray analysis of renal genes
in Clk/Clk 5/6Nx versus wild-type mice showed that the biological
pathways related to the immune system were altered (Fig. 2D; NCBI
accession no. GSE35135). Importantly, immune system function is cor-
related with inﬂammation and apoptosis (Sanz et al., 2008). The area
of F4/80-positive cells was decreased in Clk/Clk 5/6Nx mice compared
with that in wild-type 5/6Nx mice (Fig. 2E). These results suggested
that renal inﬂammation in Clk/Clk 5/6Nx mice was less than that in
WT 5/6Nx mice.
2.2. Transcriptional Control of Renal Ccl2 Expression by p65
Increased tubular expression of chemokine (C-C motif) ligand 2
(Ccl2) is observed in human progressive renal disease, and interstitial
inﬂammatory inﬁltrates express CC chemokine receptor 2 (CCR2)
(Eardley et al., 2006). Thus, we next examined the expression of Ccl2
mRNA and protein in wild-type 5/6Nx mice (Fig. 3A). Renal Ccl2
transcript levels were increased in wild-type 5/6Nx mice, peaking at
ZT6 and exhibiting a trough at ZT18 (Fig. 3B). We then investigated
the consensus sequences within the promoter region of the Ccl2 gene.
Cotransfectionwithmouse Ccl2 luciferase reporters and p65 expression
constructs led to signiﬁcant increases in transcriptional activity
(Fig. 3C). In vivo binding of the p65 protein to the p65 binding site in
the Ccl2 promoter at ZT6 was greater in lysates from 5/6Nx mice than
in lysates from Clk/Clk 5/6Nxmice (Fig. 3D). The levels of phosphorylat-
ed p65 were decreased in Clk/Clk 5/6Nx mice compared with those in
wild-type 5/6Nx mice (Fig. 3E). These results suggested that induction
of Ccl2 by p65 in Clk/Clk 5/6Nx mice was lower than that in wild-type
5/6Nx mice.
2.3. G0s2 Functioned as a Transcriptional Co-activator in Response to p65
Activation
Next, we examined the mechanism responsible for reduced the
binding of p65 to the p65 binding site in the ccl2 promoter in Clk/Clk
5/6Nx mice. In previous studies, the G0s2 has the relationship between
pathophysiology of cancer, diabetes and inﬂammation (Welch et al.,
2009, Zhang et al., 2014, Cristillo et al., 1997). And, cytosolic G0s2 is im-
portant for transactivation by p65 in inﬂammation. We demonstrated
that the microarray analysis in hepatic knockdown of G0s2 in culture
cells or mice induced the alteration of the cytokine and chemokine
signaling genes expression (Table S1A, B). Thus,we examined this inter-
action in 5/6Nx or Clk/Clk 5/6Nx kidney cell lysates by immunoprecipi-
tation. The binding of G0s2 was increased in wild-type 5/6Nx renal cell
lysates compared with that in Clk/Clk 5/6Nx renal cell lysates (Fig. 4A).
Next, to clarify the interactions between p65 and G0s2 proteins, we
performed mammalian two-hybrid assays in Hepa1-6 cells (Fig. 4B).
Co-transfection with ACT-p65 and BIND-G0s2 expression plasmids
signiﬁcantly increased the interactions of these proteins, suggesting
that there may be an interaction of between p65 and G0s2 proteins.
The transcriptional activity by of p65 was decreased by G0s2 knock-
down (Fig. 4C). Additionally, p65-dependent Ccl2 promoter activity
was suppressed byG0s2 knockdown (Fig. 4D). Next, to clarify the effects
of G0s2 on function of p65 protein, we investigated the localization of
p65 in G0s2-knockdown cells. In intact cells, G0s2 protein accumulated
in the cytosol, and p65 protein accumulated in the nucleus (Fig. 4E). In
contrast, nuclear accumulation of p65 protein and Ccl2 mRNA expres-
sion were suppressed in G0s2-knockdown cells (Fig. 4E). Moreover,
the expression of G0s2mRNA was suppressed in the kidneys of Clk/Clk
sham-operated or 5/6Nx mice compared with that in wild-type mice
Fig. 1. Renal CLOCK expression was increased in wild-type 5/6Nx mice. (A) Temporal expression proﬁles of Clock, Bmal1, Per1, Per2, Cry1, Nr1d1 (Rev-erbα), Dbp, and PparamRNA in the
kidneys of wild-type 5/6Nx and sham-operatedmice. (B) Representative temporal CLOCK protein expression proﬁles. Values are themeans± SEMs for triplicate experiments (n=3–6).
All experiments were performed three times. *P b 0.05, **P b 0.01 vs. sham-operated mice at the same time point by Bonferroni/Dunn test.
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diseases, cancer, and metabolic syndrome (Nakamura et al., 2006; Yim
et al., 2016; Yang et al., 2010; Zhang et al., 2014; Cristillo et al., 1997;Fig. 2. The progression of renal ﬁbrosis was suppressed in Clk/Clk 5/6Nxmice. (A) Serum creatin
Clk/Clkmice. (B) Left:Masson's trichome staining of tissue ﬁbrosis (blue). Right: quantitative an
tissues 8weeks after the second operation inwild-type or Clk/Clkmice. (C) Left: apoptotic cells
5/6Nxwild-type orClk/Clkmouse kidneys 8weeks after the second operation. (D) Functional an
functional annotation clustering by the Database for Annotation, Visualization, and Integra
expression proﬁles in the kidneys of sham-operated and 5/6Nx wild-type or Clk/Clkmice at Z
tissues from sham-operated and 5/6Nx wild-type or Clk/Clk mice by light microscopy 8 wee
(n= 3–6). *P b 0.05, **P b 0.01 by Bonferroni/Dunn test.Russell and Forsdyke, 1991). Thus, these results suggested that G0s2
expression may be important for the p65-dependent transcription of
inﬂammation-related genes in wild-type 5/6Nx mice.ine and serum urea nitrogen (SUN) production in sham-operated and 5/6Nx wild-type or
alysis of interstitial ﬁbrosis by lightmicroscopy in 5/6Nx and sham-operatedmouse kidney
are identiﬁed by TUNEL staining (green). Right: Caspase-3/7 activity in sham-operated and
alysis of gene expression in sham-operated and 5/6Nxwild-type and Clk/Clkmice based on
ted Discovery (DAVID). (E) Left: F4/80 immunostaining (brown). Right: F4/80 protein
eitgeber time (ZT) 6 after the second operation. Quantitative analysis of F4/80 staining in
ks after the second operation. Values are the means ± SEMs for triplicate experiments
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Fig. 3. Transcriptional control of renal Ccl2 expression by p65. (A) Left: Ccl2mRNA expression in the kidneys of sham-operated and 5/6Nx wild-type or Clk/Clkmice. Right: Ccl2 protein
expression in the kidneys of sham-operated and 5/6Nx wild-type or Clk/Clkmice. (B) Temporal proﬁles of Ccl2mRNA expression in sham-operated and 5/6Nx mice. (C) Effects of p65
transfection on mouse Ccl2-luciferase reporter activity in NIH3T3 cells. **P b 0.01 compared with the pcDNA3.1 group by Student's t-test. (D) Left: endogenous p65 protein binding to
the Ccl2 promoter in sham-operated or 5/6Nx kidney cells. (E) Renal p65 phosphorylation (Ser-536) in sham-operated and 5/6Nx wild-type or Clk/Clk mice at ZT6. Values are the
means ± SEMs for triplicate experiments (n= 3–6). **P b 0.01, *P b 0.05 vs. sham controls at the corresponding time points by Bonferroni/Dunn test.
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Activator of Transcription 5 (Stat5) Pathway in Wild-type 5/6Nx Mice
Our results described above showed that the temporal expression of
G0s2mRNA and protein peaked during the light phase in 5/6Nx mice
(Fig. 5A). The circadian oscillation of G0s2 mRNA in sham mice wasnot detected. Moreover, CKD has been shown to induce signiﬁcant
changes in the plasma levels of a myriad biomolecules, including
increased levels of serum retinol (Gibbs et al., 2014, Spengler et al.,
2012, Narasimamurthy et al., 2012). Transcription of the G0s2 gene is
controlled by the retinoic acid response element (Kitareewan et al.,
2008), and G0s2 expression exhibits a 24-h rhythm in the livers of
Fig. 4. G0s2 interacts with p65 to regulate Ccl2 expression. (A) Immunoprecipitation was performed using anti-p65 antibodies in renal cell lysates from 5/6Nx wild-type or Clk/Clkmice.
G0s2 expression in the immunoprecipitated sampleswas then analyzed byWestern blotting. (B) TheG0s2 and p65 interactionwas assessed inNIH3T3 cells usingmammalian two-hybrid
assays. Cells cotransfected with the BIND (GAL4)-p50 and ACT (VP16)-p65 expression vectors and pG5luc (GAL4 binding site promoter) luciferase reporter plasmid. (C) Upper panels
show G0s2 expression in knockdown cells. (D) Relative p65 binding element (NRE)-luciferase activity in NIH3T3 cells cotransfected with G0s2 siRNA and p65 binding element (NRE)-
luciferase plasmids. (D) Relative luciferase activity in NIH3T3 cells cotransfected with the p65 expression and Ccl2-promoter luciferase reporter plasmids and G0s2 siRNA. (E) G0s2
protein and p65 protein localization in Hepa1-6 cells. Left: cells at 48 h after GFP-G0s2 and Dsred-p65 expression vector transfection. Green: G0s2 protein; red: p65 protein. Center:
the inﬂuence of G0s2 knockdown on p65 protein localization. G0s2 mRNA-GFP, green; p65 protein (red); colocalization (orange). Right bar graph: levels of G0s2 and Ccl2 mRNAs in
G0s2-knockdown cells following transfection with the G0s2 mRNA-GFP expression vector. (F) Renal G0s2 expression in sham-operated and 5/6Nx wild-type or Clk/Clk mice at ZT6
after the second operation. Values are themeans± SEMs for triplicate experiments (n=3–6). **P b 0.01, *P b 0.05 vs. controls at the corresponding time points by Bonferroni/Dunn test.
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268 N. Matsunaga et al. / EBioMedicine 13 (2016) 262–273wild-type mice, in which G0s2 expression is elevated compared with
that in other organs (Jiang et al., 2014). Thus, we next examined the
inﬂuence of retinol production on G0s2 expression.Fig. 5. Stat5 expression and activation in 5/6Nx mouse kidneys. (A) G0s2 temporal mRNA (lef
temporal Stat5 protein phosphorylation in the kidneys of wild-type sham-operated and 5/6N
compared with the pcDNA3.1 vector control group by Student's t-test. Left: Stat5 protein bin
pcDNA3.1 in site1, site2, and site3 groups by Bonferroni/Dunn test. (C) Left: representative pr
wild-type sham-operated and 5/6Nx mice. (D) Left: Stat5a mRNA expression in sham-opera
sham-operated and 5/6Nx wild-type or Clk/Clk mice. **P b 0.01, *P b 0.05 vs. controls at the
triplicate experiments (n= 3–6).Our results showed that the rhythmic expression of G0s2 mRNA
was suppressed in livers from Clk/Clkmice (Fig. S3A). Moreover, tran-
scription of the G0s2 gene was regulated by retinoic acid receptor αt) and protein expression proﬁles. Center: Representative protein expression data. Right:
x mice. (B) Right: G0s2 promoter activity in response to Stat5 overexpression. **P b 0.01
ding to the G0s2 promoter in Stat5-transfected NIH3T3 cells. **P b 0.01 compared with
otein data. Right: temporal Stat5 phosphorylation (Tyr694/699) proﬁles in the kidneys of
ted and 5/6Nx wild-type or Clk/Clk mice. Right: Stat5 phosphorylation (Tyr694/699) in
corresponding time points by Bonferroni/Dunn test. Values are the means ± SEMs for
269N. Matsunaga et al. / EBioMedicine 13 (2016) 262–273(Rarα) and retinoic acid in ourmousemodel (Fig. S3B–G). Serum retinol
levels inwild-typemicewere alsomarkedly increased 8weeks after the
5/6Nx operation (Fig. S1F). Notably, renal RarαmRNA levels were also
markedly decreased in wild-type 5/6Nx mice at 8 weeks after the 5/6Nx
operation (Fig. S1G).
The G0s2 5′-ﬂanking region (from −2030 bp to −1057 bp) was
important for promoter activity (Fig. S3D). Moreover, this region
appeared to contain a binding site for Stat5 (Fig. 5B), which has various
roles in inﬂammation and immunity (Yu et al., 2009). Consistent with
this, cotransfectionwith themouse G0s2 luciferase reporter and Stat5 ex-
pression construct led to signiﬁcantly increased transcriptional activity
(Fig. 5B). Chromatin immunoprecipitation revealed that Stat5 may bind
to Stat5 binding site 1 in the G0s2 5′-ﬂanking region (Fig. 5B). The phos-
phorylation of Stat5 (Stat5-p) was markedly increased in the kidneys of
wild-type 5/6Nx mice (Fig. 5C), and the expressions of Stat5mRNA and
levels of Stat5-p protein were lower in the kidneys of Clk/Clk 5/6Nx
mice than in those of wild-type 5/6Nx mice (Fig. 5D).
2.5. Treatment With G0s2 siRNA or a Novel Transcriptional Inhibitor of
G0s2 Ameliorated Renal Dysfunction in Wild-type 5/6Nx Mice
Renal G0s2 expression may be important for renal inﬂammation
mediated by p65 in mice with CKD. Thus, we carried out knockdown
of G0s2 in the kidneys of 5/6Nx mice kidney (Fig. 6). Treatment of
wild-type 5/6Nxmice with control or G0s2miRNA expression plasmids
resulted in decreased levels of G0s2 and Ccl2 mRNA in the kidneysFig. 6. G0s2 knockdown ameliorated renal inﬂammation in CKD. (A) Renal expression proﬁles f
5/6Nx mice treated with control or G0s2 miRNA expression plasmids (50 μg/μL/animal, two
Bonferroni/Dunn test. (B) SUN levels in wild-type sham-operated and 5/6Nx mice treated w
from 4 to 8 weeks after the second operation. (C) Left: F4/80 immunostaining (brown) in wi
plasmids (50 μg/μL/animal, two times/week, i.v.) from 4 to 8 weeks after the second operatio
by Bonferroni/Dunn test. Values are the means ± SEMs for triplicate experiments (n= 3–6).(Fig. 6A). The phosphorylation of nuclear p65 protein was decreased
in wild-type 5/6Nx mice treated with G0s2miRNA (Fig. 6A), and SUN
concentrations decreased in 5/6Nx mice treated with G0s2 miRNA
(Fig. 6B). Finally, the F4/80-positive area and F4/80 protein levels
were decreased in 5/6Nx mice treated with G0s2 miRNA (Fig. 6C).
These results revealed that knockdown of G0s2 ameliorated renal
dysfunction in our mouse model of CKD.
In addition, we carried out high-throughput screening of 9600 small
compounds to identify novel transcriptional inhibitors of G0s2 (Figs. S4,
S5). NS-3-008 inhibited the transcription ofG0s2with a half-maximal in-
hibitory concentration (IC50) of 2.25 μM(Fig. S6).Moreover, treatment of
wild-type 5/6Nx mice with NS-3-008 (5 mg/kg, P.O.) resulted in de-
creased levels of G0s2 and Ccl2mRNA in the kidneys (Fig. 7A). The phos-
phorylation of Stat5 and p65 protein was decreased in wild-type 5/6Nx
mice treated with NS-3-008 (Fig. 7B), and SUN concentrations and
renal caspase 3/7 activity decreased in 5/6Nx mice treated with NS-03-
08 (Fig. 7). Finally, the F4/80-positive area and F4/80 protein levels
were decreased in 5/6Nxmice treated with NS-3-008 (Fig. 7D). Interest-
ingly, NS-3-008 bound toHsd17b4 (Fig. S7A–D); knockdownofHsd17b4
decreased G0s2mRNA levels, whereas overexpression of Hsd17b4 in-
duced G0s2 mRNA expression (Fig. S8A, 8B). The inhibitory effects of
NS-3-008 were blocked by knockdown of Hsd17b4 or deletion of the
Stat5 binding site in the G0s2 promoter (Fig. S8A, 8C). NS-3-008 de-
creased the nuclear phosphorylation of Stat5 (Fig. S8D). Thus, these re-
sults revealed that G0s2 inhibition by the novel compound NS-3-008
ameliorated renal dysfunction in our mouse model of CKD.or G0s2 and Ccl2mRNA and p65 protein phosphorylation in wild-type sham-operated and
times/week, i.v.) from 4 to 8 weeks after the second operation. *P b 0.05, **P b 0.01 by
ith G0s2 or control miRNA expression plasmids (50 μg/μL/animal, two times/week, i.v.)
ld-type sham-operated and 5/6Nx mice treated with G0s2 or control miRNA expression
n. Right: quantitative analysis of F4/80 staining by light microscopy. *P b 0.05, **P b 0.01
Fig. 7. Treatment with the G0s2 inhibitor NS-3-008 ameliorated renal inﬂammation in CKD. (A) Renal expression proﬁles of G0s2 and Ccl2mRNA in wild-type sham-operated and 5/6Nx
mice treatedwith NS-3-008 (5mg/kg oral [PO]) from 4 to 8weeks after the second operation. (B) Proﬁles of Stat5 phosphorylation (left) and p65 phosphorylation (right) in the kidneys of
wild-type sham-operated and 5/6Nx mice treated with NS-3-008 (5mg/kg, PO) 4 to 8 weeks after the second operation. (C) SUN (left) and renal caspase 3/7 activity (right) in wild-type
sham-operated and5/6Nxmice treatedwithNS-3-008 (5mg/kg, PO) 4 to 8weeks after the second operation. (D) Left: F4/80 immunostaining (brown) inwild-type sham-operated and5/
6Nx mice treated with NS-3-008 (5 mg/kg, PO) from 4 to 8 weeks after the second operation. Right: quantitative analysis of F4/80 staining by light microscopy. *P b 0.05, **P b 0.01 by
Bonferroni/Dunn test. Values are the means ± SEMs for triplicate experiments (n= 3–6).
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In patients with CKD, the circadian rhythm and serum hormone
levels are dysregulated (Niemczyk et al., 2006). Moreover, inﬂamma-
tion, which can be mediated by the molecular clock (Hashiramoto et
al., 2010), is related to the pathology of CKD (Yu et al., 2014). Thus, in
this study, we aimed to examine the relationships between circadian
rhythms and CKD pathology. To this end, we investigated the role of
G0s2 in CKD. Our data indicated that G0s2may aggravate renal dysfunc-
tion in the context of CKD through mechanisms involving increased
renal expression of the Clock gene. Subsequent induction of G0s2expression by Stat5 in the kidneymay further exacerbate renal dysfunc-
tion by inducing inﬂammation. These data, combined with our identiﬁ-
cation of a novel G0s2 inhibitor, suggest that G0s2 may be a promising
therapeutic target in the treatment of CKD.
The molecular clock system is important for renal function in wild-
type mice (Zuber et al., 2009; Nikolaeva et al., 2012). In this study, we
found that the expression of renal clock genes was altered in kidneys
from 5/6Nx mice, suggesting that increased expression of CLOCK,
which is important for the core loop in the circadian clock system and
is involved in inﬂammation, may affect the expression of other clock
genes. Interestingly, we also found that mutations in the Clock gene
271N. Matsunaga et al. / EBioMedicine 13 (2016) 262–273ameliorated renal ﬁbrosis, apoptosis, and inﬂammatory reactions in
mice with CKD. Circadian proteins are known to regulate both blood
pressure and kidney function (Curtis et al., 2007; Stow et al., 2012;
Doi et al., 2010). In this study, we found that AT II levels in Clk/Clk
mice were higher than those in wild-type mice (Fig. S1D). In addition,
food intake in mice affects AT II levels, which are also highly dependent
on salt intake and renal perfusion pressure. No signiﬁcant changes were
observed in the amount of food and water intake between wild-type
and Clk/Clk mice in this study (Fig. S1E). In addition, angiotensin-
converting enzyme (ACE) levels in the lungs at ZT8were higher in intact
Clk/Clkmice than in intact wild-type mice (Fig. S1E). In addition, there
were no differences in mean blood pressure (MBP) increases between
5/6Nx wild-type mice and 5/6Nx Clk/Clk mice (Fig. S1E). This may
have contributed to the clock-related pathology observed in our
model. Renal ﬁbrosis, apoptosis, and inﬂammation were ameliorated
in Clk/Clk mice following the 5/6Nx procedure. These data provided
insights into the mechanisms of renal inﬂammatory reactions induced
by Clock, directing our further studies.
Ccl2 is expressed at sites of injury and inﬂammation to direct
macrophage recruitment; it binds with CCR2 to promote macrophage
adhesion and chemotaxis to disease sites. Increased tubular expression
of CCL2 is present in human progressive renal disease, and interstitial
inﬂammatory inﬁltrates express CCR2 (Eardley et al., 2006). Although
Ccl2 expression was increased in wild-type 5/6Nxmice, this phenotype
was not observed in Clk/Clk mice. Moreover, Ccl2 mRNA expression
varied in a time-dependent manner in wild-type 5/6Nx mice and was
regulated by p65. The expression of Ccl2 is activated by binding of tran-
scription factors to NF-κB elements in the Ccl2 promoter (Deng et al.,
2013). Although the CLOCK protein enhances transcription mediated
by NF-κB, CLOCKΔ19 protein does not affect NF-κB-dependent tran-
scription (Spengler et al., 2012), and the mechanism by which NF-κB
regulates transcription in Clk/Clk mice remains unclear. In our study,
we showed that G0s2, which is involved in the transition from G0
phase to G1 phase and is mediated by cyclosporine A (Cristillo et al.,
1997), interacted with p65 protein in the kidneys of wild-type 5/6Nx
mice. Nuclear accumulation of p65 protein was suppressed in G0s2-
knockdown cells. Therefore, G0s2 protein may promote the nuclear
localization of p65 protein. Moreover, knockdown of G0s2 blocked the
transactivation of renal Ccl2 expression and the progression of renal
dysfunction. KnockdownofG0s2 also reduced thenumber of F4/80-pos-
itive cells. These effects were also identiﬁed in a diethylnitrosamine
(DEN) hepatitis mouse model (Fig. S2A–C). G0s2 mRNA expression
was also decreased in the kidneys of Clk/Clk 5/6Nx mice, suggesting
that G0s2 may be a novel activator of inﬂammatory reactions via p65
in 5/6Nx mice. Further analysis showed that repression of G0s2 expres-
sion in Clk/Clk 5/6Nx mice may be related to the lack of induction of
Stat5, which has been shown to be directly regulated by the molecular
clock in humans and rodents (Mavroudis et al., 2013). Thus, these
data provided important insights into the regulation of inﬂammation
and CKD by G0s2 and related pathways.
Chemical screening is a powerful tool to investigate various biologi-
cal pathways (Pieper et al., 2010). Several recent studies have employed
cell-based chemical screening strategies to identify small molecules
with biological activities (Chen et al., 2012), providing evidence
supporting the use of chemical screening approaches. In this study, we
performed a high-throughput chemical screen of 9600 synthetic small
molecules from a chemical library (Open Innovation Centre for Drug
Discovery, The University of Tokyo) to identify transcriptional inhibitors
of G0s2. Administration of NS-3-008 inhibited the expression of G0s2 in
healthymice liver. In contrast, administration of NS-3-008 did not affect
the MBP in wild-type sham and 5/6Nxmice. We identiﬁed NS-3-008 as
a novel G0s2 inhibitor and showed that administration of this inhibitor
ameliorated renal dysfunction in wild-type 5/6Nxmice. In addition, the
lipopolysaccharide (LPS)- or tumor necrosis factor alpha (TNFα)-
dependent transactivation of G0s2 and Ccl2 was inhibited by adminis-
tration of NS-3-008 (Fig. S10A–E). Moreover, NS-3-008 bound toHsd17b4 to block G0s2 expression. Similar studies have shown that
chromeceptin affects the transcription by Stats via binding to Hsd17b4
(Choi et al., 2006). Thus, our experiments identiﬁed a novel inhibitor
of G0s2 and provided evidence for the mechanism of inhibition by this
novel inhibitor, supporting the potential utility of G0s2 inhibition in
the treatment of CKD.
In conclusion, our results showed that altered expression of molecu-
lar components of the clock signaling machinery was associated with
the degree of CKD pathology. Environmental factors, such as light expo-
sure, feeding habits, and working conditions, in human societies are
complex; although these environmental conditionsmay also contribute
to the observed effects, our data clearly indicated that inhibition of G0s2
function may have therapeutic beneﬁts in the treatment of CKD.
4. Experimental Procedures
4.1. Mouse Experiments
Male ICR mice (Charles River Laboratory Japan, Inc.; Yokohama,
Japan) were housed in a light-controlled room (lights on from ZT0 to
ZT12) at 24± 1 °C and 60%± 10% humidity, with food andwater avail-
able ad libitum. Mice were synchronized to the light/dark cycle for
2 weeks before surgery. Clock mutant mice (C57BL/6J-ClockmlJt/J)
were purchased from the Jackson Laboratory (Bar Harbor, ME, USA)
and backcrossed to wild-type Jcl: ICR mice for more than eight
generations to enhance breeding and offspring care. Experiments
were performed using wild-type ICR, homogeneous, and Clock-mutant
mice. CKDwas induced in 6-week-oldmice by 5/6Nx two-stage surgery
under isoﬂurane anesthesia (Baxter, Deerﬁeld, IL, USA). During the ﬁrst
procedure, two-thirds of the left kidney was removed by cutting off
both poles. Seven days later, the right kidney was completely removed.
After the operations, mice were housed for 8 weeks to allow CKD
development. Sham mice were subjected to laparotomy on the same
days as the 5/6Nx mouse surgeries. For G0s2 inhibitor NS-3-008
treatment, mice were administered NS-3-008 (5 mg/kg body weight)
or vehicle control in the drinking water from weeks 4 to 8 following
the second 5/6Nx operation. All animals used in this studywere treated
in accordancewith the guidelines stipulated by the Animal Care andUse
Committee of Kyushu University.
4.2. Cell Culture
NIH3T3 cells (supplied by the Cell Resource Center for Biochemical
Research, Tohoku University) were grown at 37 °C in a humidiﬁed
environment (5% CO2, 95% air) in Dulbecco's modiﬁed Eagle's medium
(Sigma-Aldrich; St. Louis, MO, USA) containing 10% fetal bovine serum
(SAFC Biosciences; Kansas City, MO, USA), 0.1 μM insulin, 0.1 μM dexa-
methasone, and 2% penicillin/streptomycin.
4.3. Statistical Analysis
All data represent the mean ± standard error of the mean (SEM) of
at least three individual experiments. Differences were assessed using
Student's t or analysis of variance (ANOVA) with Bonferroni/Dunn
post hoc testing as indicated. P N 0.05 was considered statistically
signiﬁcant.
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